AMENDMENT TO COMMITMENT LETTERSalix Pharmaceuticals LTD • December 3rd, 2013 • Pharmaceutical preparations • New York
We refer to that certain Commitment Letter, dated November 7, 2013 (including the exhibits, schedules and annexes thereto, the “Commitment Letter”) between us and you. Terms used but not defined in this letter agreement (this “Amendment to Commitment Letter”) shall have the meanings assigned thereto in the Commitment Letter.
SANTARUS, INC.Salix Pharmaceuticals LTD • December 3rd, 2013 • Pharmaceutical preparations
Willow Acquisition Sub Corporation, a Delaware corporation (“Purchaser,” “we,” “our” or “us”) and an indirect wholly owned subsidiary of Salix Pharmaceuticals, Ltd., a Delaware corporation (“Salix”), is offering to purchase all of the issued and outstanding shares of common stock, par value $0.0001 par value, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share (collectively, the “Shares”), of Santarus, Inc., a Delaware corporation (“Santarus”), at a purchase price of $32.00 per Share, net to the seller in cash (the “Offer Price”), without interest thereon and subject to any required withholding taxes, upon the terms and subject to the conditions set forth in this offer to purchase (the “Offer to Purchase”) and in the related letter of transmittal (the “Letter of Transmittal”), which, together with the Offer to Purchase, each as may be amended or supplemented from time to time, collectively constitute the “Offe
